Editorial on Translational Research in Graft-Versus-Host Disease (GVHD) and Graft-Versus-Tumor (GVT) Effect After Allogeneic Hematopoietic Cell Transplantation.
作者信息
Czech Marie, Zeiser Robert, Toubai Tomomi
机构信息
Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Faculty of Biology, University of Freiburg, Freiburg, Germany.
出版信息
Front Immunol. 2022 Jun 8;13:948720. doi: 10.3389/fimmu.2022.948720. eCollection 2022.
Abstract
摘要
相似文献
1
Editorial on Translational Research in Graft-Versus-Host Disease (GVHD) and Graft-Versus-Tumor (GVT) Effect After Allogeneic Hematopoietic Cell Transplantation.异基因造血细胞移植后移植物抗宿主病（GVHD）及移植物抗肿瘤（GVT）效应的转化研究述评
Front Immunol. 2022 Jun 8;13:948720. doi: 10.3389/fimmu.2022.948720. eCollection 2022.
2
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.异基因反应性作为血液系统恶性肿瘤治疗的治疗原则。非清髓性预处理的异基因造血细胞移植的临床和免疫学方面的研究。
Dan Med Bull. 2007 May;54(2):112-39.
3
Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.异基因造血干细胞移植后的移植物抗宿主病可诱导一种CD8 + T细胞介导的移植物抗肿瘤效应，该效应不依赖于对同种异体抗原性肿瘤靶点的识别。
Blood. 2004 Aug 15;104(4):1210-6. doi: 10.1182/blood-2003-10-3387. Epub 2004 Apr 15.
4
The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity.干扰素-γ在移植物抗宿主病和移植物抗肿瘤活性中的复杂核心作用。
Immunol Rev. 2014 Mar;258(1):30-44. doi: 10.1111/imr.12151.
5
Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.针对自体干细胞移植后复发患者的异基因细胞疗法。
Biol Blood Marrow Transplant. 2001;7(4):230-8. doi: 10.1053/bbmt.2001.v7.pm11349810.
6
Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.同种异体造血细胞移植中的细胞毒性途径。
Front Immunol. 2018 Dec 19;9:2979. doi: 10.3389/fimmu.2018.02979. eCollection 2018.
7
Immunobiology of allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植的免疫生物学
Annu Rev Immunol. 2007;25:139-70. doi: 10.1146/annurev.immunol.25.022106.141606.
8
Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma.移植物抗淋巴瘤效应在非霍奇金淋巴瘤的各种组织学类型中的表现
Leuk Lymphoma. 2003;44 Suppl 3:S99-105. doi: 10.1080/10428190310001623694.
9
The graft-versus-tumor effect in pediatric malignancy.移植物抗白血病效应在儿科恶性肿瘤中的作用。
Pediatr Clin North Am. 2010 Feb;57(1):67-81. doi: 10.1016/j.pcl.2009.12.002.
10
Editorial: Interferons and GvHD.社论：干扰素与移植物抗宿主病
Front Immunol. 2022 Feb 3;13:853567. doi: 10.3389/fimmu.2022.853567. eCollection 2022.
本文引用的文献
1
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.芦可替尼治疗糖皮质激素难治性慢性移植物抗宿主病。
N Engl J Med. 2021 Jul 15;385(3):228-238. doi: 10.1056/NEJMoa2033122.
2
Acute Graft-versus-Host-Disease Other Than Typical Targets: Between Myths and Facts.非典型靶器官的急性移植物抗宿主病：在神话与现实之间。
Transplant Cell Ther. 2021 Feb;27(2):115-124. doi: 10.1016/j.bbmt.2020.09.033. Epub 2020 Oct 2.
3
Noninfectious neurologic complications of hematopoietic cell transplantation: A systematic review.造血细胞移植的非感染性神经系统并发症：系统评价。
Hematol Oncol Stem Cell Ther. 2021 Jun;14(2):87-94. doi: 10.1016/j.hemonc.2020.05.006. Epub 2020 May 21.
4
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.芦可替尼治疗糖皮质激素难治性急性移植物抗宿主病。
N Engl J Med. 2020 May 7;382(19):1800-1810. doi: 10.1056/NEJMoa1917635. Epub 2020 Apr 22.
5
Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia.中枢神经系统移植物抗宿主病是由小胶质细胞中 TNF 的上调介导的。
J Clin Invest. 2020 Mar 2;130(3):1315-1329. doi: 10.1172/JCI130272.
6
Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children.儿童异基因造血干细胞移植后的中枢神经系统并发症。
Acta Haematol. 2019;142(4):217-223. doi: 10.1159/000499651. Epub 2019 Oct 9.
7
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.索拉非尼通过 FLT3-ITD 突变白血病细胞中白细胞介素 15 的产生促进小鼠和人类中的移植物抗白血病活性。
Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12.
8
Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.急性移植物抗宿主病——生物学过程、预防与治疗
N Engl J Med. 2017 Nov 30;377(22):2167-2179. doi: 10.1056/NEJMra1609337.
9
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.急性髓系白血病和骨髓增生异常综合征的清髓性与减低强度造血细胞移植
J Clin Oncol. 2017 Apr 10;35(11):1154-1161. doi: 10.1200/JCO.2016.70.7091. Epub 2017 Feb 13.
10
Prognostic Limitations of Donor T Cell Chimerism after Myeloablative Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.清髓性异基因干细胞移植治疗急性髓系白血病和骨髓增生异常综合征后供体T细胞嵌合状态的预后局限性
Biol Blood Marrow Transplant. 2017 May;23(5):840-844. doi: 10.1016/j.bbmt.2017.01.086. Epub 2017 Feb 6.
Zotero 插件